FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang.

"We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success."

Elaine M. Yang is the chief revenue officer of Lyra Health, Inc. and oversees Lyra's go-to-market functions including marketing, sales, sales operations and customer success. Previously, she also served as the company's vice president of operations responsible for building the company's business operations departments. Prior to joining Lyra, Ms. Yang was the vice president of internal audit at Facebook, where she established the function that was tasked with assessing risk as the company transitioned to being publicly traded. From 1992 to 2009, she was with Genentech building and managing finance and audit teams. Ms. Yang holds a B.A. in Political Science from the University of Redlands in California.

The company also announced that Kleanthis Xanthopoulos, Ph.D., will step down from Zosano's board of directors effective December 31, 2021. Mr. Lo added, "Since 2013, Dr. Xanthopoulos has been an important contributor to Zosano and on behalf of the entire board and the company, I want to extend our gratitude to Kleanthis for his years of service to Zosano."

About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.